Armen Asatryan
Publications by Year
Research Areas
Hepatitis C virus research, HIV/AIDS drug development and treatment, Systemic Lupus Erythematosus Research, Liver Disease Diagnosis and Treatment, Hepatitis B Virus Studies
Most-Cited Works
- → Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection(2018)430 cited
- → Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis(2017)296 cited
- → Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment(2017)201 cited
- → Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure(2017)137 cited
- → Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis(2016)115 cited
- → High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis(2016)102 cited
- → Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high‐fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib(2017)65 cited
- → Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection(2015)61 cited
- → Glecaprevir–pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies—a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2)(2020)52 cited
- → Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis(2018)41 cited